PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of genannJournal InfoAuthorsPermissionsJournals.ASM.orggenomeA ArticleGenome Announcements
 
Genome Announc. 2017 April; 5(14): e00053-17.
Published online 2017 April 6. doi:  10.1128/genomeA.00053-17
PMCID: PMC5383878

Whole-Genome Sequences of Burkholderia pseudomallei Isolates Exhibiting Decreased Meropenem Susceptibility

ABSTRACT

We report here paired isogenic Burkholderia pseudomallei genomes obtained from three patients receiving intravenous meropenem for melioidosis treatment, with post-meropenem isolates developing decreased susceptibility. Two genomes were finished, and four were drafted to improved high-quality standard. These genomes will be used to identify meropenem resistance mechanisms in B. pseudomallei.

GENOME ANNOUNCEMENT

Burkholderia pseudomallei is a Gram-negative soil- and water-borne bacterium that causes the tropical infectious disease melioidosis. Melioidosis severity ranges widely, with the most serious form of disease, septic shock, resulting in fatality in up to 95% of untreated cases (1). B. pseudomallei is intrinsically resistant to many antibiotics commonly used in sepsis treatment, limiting treatment options and often resulting in progressive disease when not diagnosed (2, 3). In Australia, where melioidosis mortality rates have decreased to approximately 10% (4), ceftazidime is the mainstay of intravenous therapy for melioidosis, with meropenem usually reserved for life-threatening sepsis requiring intensive care therapy (5). We recently identified three Australian blood culture-persistent patients in whom decreased meropenem sensitivity has been observed (D.S. Sarovich, J. R. Webb, M. C. Pitman, L. Viberg, M. Mayo, R. W. Baird, B. J. Currie, E. P. Price, unpublished data); this is the first time that this phenomenon has been reported. Identifying the molecular mechanisms underpinning decreased meropenem susceptibility in B. pseudomallei is vital in detecting resistance emergence toward this life-saving antibiotic. The genome of another clinical isolate of B. pseudomallei with imipenem resistance, a related carbapenem, has recently been described (6).

Three paired isogenic B. pseudomallei isolates were examined in this study (Table 1). The first isolates were sensitive toward meropenem, whereas the latter isolates had decreased sensitivity according to MIC testing. The six isolates were extracted as previously described (7), with the addition of RNase treatment. Genomic DNA was subjected to Illumina paired-end HiSeq2000 whole-genome sequencing (Macrogen Inc., Geumcheon-gu, Seoul, Republic of Korea) to ~55× coverage. In addition, PacBio single-molecule real-time sequencing was conducted on the PacBio RS II instrument (Institute for Genome Sciences, Baltimore, MD, USA) to ~13× coverage using 20-kb SMRTbell libraries and P6C4 chemistry.

TABLE 1
Isogenic B. pseudomallei strains sequenced in this study

PacBio genomic data were assembled using HGAP.3 (8) (MSHR strains 3763, 4083, and 5864), Celera Assembler version 8.2 (9) (MSHR strain 6522), and Celera Assembler version 8.3 (MSHR strains 6755 and 7929). Assemblies were reorganized relative to the closed B. pseudomallei K96243 genome (10) (GenBank accession no. CP009538 and CP009537) with the assistance of progressiveMAUVE (11), followed by error-correction with the Illumina reads using iCORN2 (12). For MSHR strains 3763 and 4083, SPANDx version 3.1 (13) was used to identify a handful of remaining errors in the assemblies, which were manually corrected and verified by repeat analysis in SPANDx. All variants were also confirmed by comparison of the MSHR strain 3763 and MSHR strain 4083 assemblies using Illumina-only assemblies generated by MGAP.

The development of B. pseudomallei resistance toward meropenem is of great concern, as this drug is one of a handful of efficacious antimicrobials for melioidosis treatment. Meropenem resistance is especially concerning given that this antibiotic is used to treat the most severe melioidosis cases in Australia and some other melioidosis-endemic regions. Treatment failure in such cases must be rapidly identified in the clinical setting to enable clinicians to alter therapy in close-to-real time. The six genomes reported in this study will be used to search for genetic variants imparting decreased meropenem susceptibility in B. pseudomallei.

Accession number(s).

The genome sequences of the B. pseudomallei isolates reported here have been deposited in GenBank under the accession numbers listed in Table 1.

ACKNOWLEDGMENTS

We thank the Microbiology Laboratory scientists at Royal Darwin Hospital and Mark Mayo and Vanessa Theobald for isolate identification and laboratory assistance. Funding for this project was provided by the Australian National Health and Medical Research Council via awards 1046812 and 1098337, with the PacBio sequencing funded by the Pacific Biosciences SMRTest Microbe 2015 Grant Program, of which E.P.P. was the recipient. E.P.P. was funded by a USC Research Fellowship. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Footnotes

Citation Price EP, Smith ML, Paxinos EE, Tallon LJ, Sadzewicz L, Sengamalay N, Baird RW, Currie BJ, Sarovich DS. 2017. Whole-genome sequences of Burkholderia pseudomallei isolates exhibiting decreased meropenem susceptibility. Genome Announc 5:e00053-17. https://doi.org/10.1128/genomeA.00053-17.

REFERENCES

1. Cheng AC, Stephens DP, Anstey NM, Currie BJ 2004. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 38:32–37. doi:.10.1086/380456 [PubMed] [Cross Ref]
2. Wuthiekanun V, Amornchai P, Saiprom N, Chantratita N, Chierakul W, Koh GC, Chaowagul W, Day NP, Limmathurotsakul D, Peacock SJ 2011. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in northeast Thailand. Antimicrob Agents Chemother 55:5388–5391. doi:.10.1128/AAC.05517-11 [PMC free article] [PubMed] [Cross Ref]
3. Dance D. 2014. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 43:310–318. doi:.10.1016/j.ijantimicag.2014.01.005 [PMC free article] [PubMed] [Cross Ref]
4. Currie BJ. 2015. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 36:111–125. doi:.10.1055/s-0034-1398389 [PubMed] [Cross Ref]
5. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ 2004. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 48:1763–1765. [PMC free article] [PubMed]
6. Bugrysheva JV, Sue D, Hakovirta J, Loparev VN, Knipe K, Sammons SA, Ranganathan-Ganakammal S, Changayil S, Srinivasamoorthy G, Weil MR, Tatusov RL, Gee JE, Elrod MG, Hoffmaster AR, Weigel LM 2015. Finished annotated genome sequence of Burkholderia pseudomallei strain Bp1651, a multidrug-resistant clinical isolate. Genome Announc 3(6):e01427-15. doi:.10.1128/genomeA.01427-15 [PMC free article] [PubMed] [Cross Ref]
7. Currie BJ, Gal D, Mayo M, Ward L, Godoy D, Spratt BG, LiPuma JJ 2007. Using BOX-PCR to exclude a clonal outbreak of melioidosis. BMC Infect Dis 7:68. doi:.10.1186/1471-2334-7-68 [PMC free article] [PubMed] [Cross Ref]
8. Chin CS, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, Clum A, Copeland A, Huddleston J, Eichler EE, Turner SW, Korlach J 2013. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nat Methods 10:563–569. doi:.10.1038/nmeth.2474 [PubMed] [Cross Ref]
9. Myers EW, Sutton GG, Delcher AL, Dew IM, Fasulo DP, Flanigan MJ, Kravitz SA, Mobarry CM, Reinert KH, Remington KA, Anson EL, Bolanos RA, Chou HH, Jordan CM, Halpern AL, Lonardi S, Beasley EM, Brandon RC, Chen L, Dunn PJ, Lai Z, Liang Y, Nusskern DR, Zhan M, Zhang Q, Zheng X, Rubin GM, Adams MD, Venter JC 2000. A whole-genome assembly of Drosophila. Science 287:2196–2204. [PubMed]
10. Johnson SL, Bishop-Lilly KA, Ladner JT, Daligault HE, Davenport KW, Jaissle J, Frey KG, Koroleva GI, Bruce DC, Coyne SR, Broomall SM, Ketheesan N, Mayo M, Hoffmaster AR, Elrod MG, Wuthiekanun V, Tuanyok A, Norton R, Currie BJ, Wagner DM, Keim P, Li PE, Teshima H, Gibbons HS, Palacios GF, Rosenzweig CN, Redden CL, Xu Y, Minogue TD, Chain PS 2016. Correction for Johnson et al., Complete genome sequences for 59 Burkholderia isolates, both pathogenic and near neighbor. Genome Announc 4(2):e00313-16. doi:.10.1128/genomeA.00313-16 [PMC free article] [PubMed] [Cross Ref]
11. Darling AE, Mau B, Perna NT 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One 5:e11147. doi:.10.1371/journal.pone.0011147 [PMC free article] [PubMed] [Cross Ref]
12. Otto TD, Sanders M, Berriman M, Newbold C 2010. Iterative correction of reference nucleotides (iCORN) using second generation sequencing technology. Bioinformatics 26:1704–1707. doi:.10.1093/bioinformatics/btq269 [PMC free article] [PubMed] [Cross Ref]
13. Sarovich DS, Price EP 2014. SPANDx: a genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. BMC Res Notes 7:618. doi:.10.1186/1756-0500-7-618 [PMC free article] [PubMed] [Cross Ref]
14. Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, Ali J, Birren B, Bruce DC, Buhay C, Cole JR, Ding Y, Dugan S, Field D, Garrity GM, Gibbs R, Graves T, Han CS, Harrison SH, Highlander S, Hugenholtz P, Khouri HM, Kodira CD, Kolker E, Kyrpides NC, Lang D, Lapidus A, Malfatti SA, Markowitz V, Metha T, Nelson KE, Parkhill J, Pitluck S, Qin X, Read TD, Schmutz J, Sozhamannan S, Sterk P, Strausberg RL, Sutton G, Thomson NR, Tiedje JM, Weinstock G, Wollam A, Consortium Genomic Standards Consortium Human Microbiome Project Jumpstart 2009. Genome project standards in a new era of sequencing. Science 326:236–237. doi:.10.1126/science.1180614 [PMC free article] [PubMed] [Cross Ref]

Articles from Genome Announcements are provided here courtesy of American Society for Microbiology (ASM)